CD34 and neoplasm: Newly formed α-SMA-positive myofibroblasts are presumed not to retain the immunological functions of CD34-positive fibroblasts from which they originated, nor their capacity for stromal remodeling and regulation of angiogenesis, which may significantly influence further tumor progression and dissemination [34,36,43,44].